Pfizer Market Cap 2010-2025 | PFE

Pfizer market cap history and chart from 2010 to 2025. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Pfizer market cap as of June 12, 2025 is $141.22B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $141.224B $63.627B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $769.590B 59.01
Johnson & Johnson (JNJ) United States $376.935B 15.59
AbbVie (ABBV) United States $339.891B 18.74
Roche Holding AG (RHHBY) Switzerland $267.554B 0.00
Novartis AG (NVS) Switzerland $255.117B 14.57
Merck (MRK) United States $205.453B 10.50
Sanofi (SNY) France $124.659B 12.28
Bayer (BAYRY) Germany $31.555B 6.42
Innoviva (INVA) United States $1.343B 14.08
Novo Nordisk (NVO) Denmark $0.000B 23.98